F009 The Changing Landscape of Early-stage Melanoma Management
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
There have been many recent advances in our understanding of potential therapeutic and management options for patients with early-stage melanoma (melanoma confined only to the skin). This session discusses incorporating this information into practice as well as reviewing clinical trials of potential therapeutic options. Topics include an update on total body imaging options, a literature update relevant to patients with melanoma or at risk for melanoma, how to choose genetic testing for melanoma patients or those at risk, current options for ancillary tumor testing, and a review of the role of adjuvant therapy in the early-stage melanoma population.
LEARNING OBJECTIVES
Discuss available genetic testing options for patients with melanoma or at risk for melanoma, and available ancillary tumor testing options.
Discuss the potential role of adjuvant therapy in patients with melanoma confined only to the skin.
Describe total body imaging options and describe recent literature findings of relevance to patients with melanoma or at risk for melanoma.
SCHEDULE
5:00 PM
Introduction
Michael E. Ming, MD, FAAD
5:05 PM
The State of Total Body Imaging
Kelly C Nelson, MD, FAAD
5:25 PM
Melanoma Literature Update
Michael E. Ming, MD, FAAD
5:45 PM
Genetic Testing and Melanoma
Emily Y. Chu, MD, PhD, FAAD
6:05 PM
Current Options for Ancillary Tumor Testing
Rebecca I Hartman, MD, MPH, FAAD
6:25 PM
Emerging Therapeutic Options for Higher-Risk Melanoma
John Miura, MD
6:45 PM
Q&A
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
Rebecca I Hartman, MD, MPH, FAAD
Michael E. Ming, MD, FAAD
John Miura, MD
Kelly C Nelson, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Rebecca I Hartman, MD, MPH, FAAD
Almirall – Consultant (1099 relationship)(Fees); Evereden – Advisory Board(Stock), Consultant(Fees); Med Learning Group – Speaker/Faculty Education(Fees); MJH Life Sciences – Consultant (1099 relationship)(Fees); Oasis Pharmaceuticals – Data Safety Monitoring Board(Fees);
Michael E. Ming, MD, FAAD
No financial relationships exist with ineligible companies.
John Miura, MD
No financial relationships exist with ineligible companies.
Kelly C Nelson, MD, FAAD
No financial relationships exist with ineligible companies.